Bone marrow stromal cells with a combined expression of BMP-2 and VEGF-165 enhanced bone regeneration

2011 ◽  
Vol 6 (1) ◽  
pp. 015013 ◽  
Author(s):  
Caiwen Xiao ◽  
Huifang Zhou ◽  
Guangpeng Liu ◽  
Peng Zhang ◽  
Yao Fu ◽  
...  
Nanoscale ◽  
2020 ◽  
Vol 12 (13) ◽  
pp. 7284-7300 ◽  
Author(s):  
Xiangfeng Li ◽  
Minjun Liu ◽  
Fuying Chen ◽  
Yuyi Wang ◽  
Menglu Wang ◽  
...  

Biomimicking the nanostructure of natural bone apatite to enhance the bioactivity of hydroxyapatite (HA) biomaterials is an eternal topic in the bone regeneration field.


2010 ◽  
Vol 16 (2) ◽  
pp. 489-499 ◽  
Author(s):  
Paolo Giannoni ◽  
Silvia Scaglione ◽  
Antonio Daga ◽  
Cristina Ilengo ◽  
Michele Cilli ◽  
...  

2009 ◽  
Vol 15 (7) ◽  
pp. 1489-1499 ◽  
Author(s):  
Ichiro Torigoe ◽  
Shinichi Sotome ◽  
Akio Tsuchiya ◽  
Toshitaka Yoshii ◽  
Hidetsugu Maehara ◽  
...  

2019 ◽  
Vol 30 (S19) ◽  
pp. 79-79
Author(s):  
Fumio Suehiro ◽  
Masakazu Ishii ◽  
Naohiro Komabashiri ◽  
Tomohiro Masuzaki ◽  
Shinichiro Kawamoto ◽  
...  

Bone ◽  
2015 ◽  
Vol 70 ◽  
pp. 87-92 ◽  
Author(s):  
Pamela G. Robey ◽  
Sergei A. Kuznetsov ◽  
Jiaqiang Ren ◽  
Harvey G. Klein ◽  
Marianna Sabatino ◽  
...  

Nanoscale ◽  
2019 ◽  
Vol 11 (43) ◽  
pp. 20884-20892 ◽  
Author(s):  
Zhong-Wei Luo ◽  
Fu-Xing-Zi Li ◽  
Yi-Wei Liu ◽  
Shan-Shan Rao ◽  
Hao Yin ◽  
...  

A novel strategy to deliver therapeutic exosomes to bone is developed for the first time by conjugating a specific BMSC-targeting aptamer to the exosomal surface.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Justyna Magdalena Kowal ◽  
Sören Möller ◽  
Dalia Ali ◽  
Florence Figeac ◽  
Torben Barington ◽  
...  

Abstract Background Transplantation of human bone marrow stromal cells (hBMSCs) is a promising therapy for bone regeneration due to their ability to differentiate into bone forming osteoblastic cells. However, transplanted hBMSCs exhibit variable capacity for bone formation resulting in inconsistent clinical outcome. The aim of the study was to identify a set of donor- and cell-related characteristics that detect hBMSCs with optimal osteoblastic differentiation capacity. Methods We collected hBMSCs from 58 patients undergoing surgery for bone fracture. Clinical profile of the donors and in vitro characteristics of cultured hBMSCs were included in uni- and multivariable analysis to determine their predictive value for osteoblastic versus adipocytic differentiation capacity assessed by quantification of mineralized matrix and mature adipocyte formation, respectively. Results We identified a signature that explained > 50% of variation in osteoblastic differentiation outcome which included the following positive predictors: donor sex (male), absence of osteoporosis diagnosis, intake of vitamin D supplements, higher fraction of CD146+, and alkaline phosphate (ALP+) cells. With the exception of vitamin D and ALP+ cells, these variables were also negative predictors of adipocytic differentiation. Conclusions Using a combination of clinical and cellular criteria, it is possible to predict differentiation outcome of hBMSCs. This signature may be helpful in selecting donor cells in clinical trials of bone regeneration.


Sign in / Sign up

Export Citation Format

Share Document